Neurocrine Biosciences, Inc. (NBIX)

Market Cap	14.28B
Revenue (ttm)	2.68B
Net Income (ttm)	428.00M
Shares Out	99.71M
EPS (ttm)	4.19
PE Ratio	34.17
Forward PE	16.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,036,773
Open	138.04
Previous Close	138.04
Day's Range	137.07 - 143.47
52-Week Range	84.23 - 154.61
Beta	0.21
Analysts	Strong Buy
Price Target	170.17 (+18.83%)
Earnings Date	Oct 28, 2025

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX
• Website: https://www.neurocrine.com

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Analyst Summary

According to 18 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $170.17, which is an increase of 18.83% from the latest price.

Price Target

$170.17

(18.83% upside)

Analyst Consensus: Strong Buy